The Week Ahead: Fed...
Health Care: Drugs
Neuralstem Inc. (CUR: AMEX)
$0.92 -0.01 | -1.06%
06/04/12 - 03:56 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 390.62K | 733.44K | 0.00 | 0.00 |
| Cost of Sales | 0.00 | -1.00 | 0.00 | 0.00 |
| Gross Operating Profit | 390.62K | 733.44K | 0.00 | 0.00 |
| Selling, General, and Administrative Expenses | 5.84M | 6.62M | 5.03M | 5.25M |
| Research & Development | 7.35M | 9.16M | 5.35M | 6.51M |
| Operating Income before D & A (EBITDA) | -12.80M | -15.05M | -10.38M | -11.77M |
| Depreciation & Amortization | 187.05K | 130.75K | 88.66K | 66.00K |
| Interest Income | 60.96K | 59.28K | 19.61K | 40.00K |
| Other Income - Net | 411.81K | -3.26M | 83.35K | -39.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -12.52M | -18.38M | -10.36M | -11.83M |
| Interest Expense | 821.00 | 2.66K | 776.00 | 0.00 |
| Pre-Tax Income | -12.52M | -18.39M | -10.36M | -11.83M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -12.52M | -18.39M | -10.36M | -11.83M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -12.52M | -18.39M | -10.36M | -11.83M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -12.52M | -18.39M | -10.36M | -11.83M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-12.52M | -18.39M | -10.36M | -11.83M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -12.52M | -18.39M | -10.36M | -11.83M |
| Basic EPS from Continuing Ops. | -0.26 | -0.42 | -0.30 | -0.37 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.26 | -0.42 | -0.30 | -0.37 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.26 | -0.42 | -0.30 | -0.37 |
| Basic Normalized Net Income/Share | -0.26 | -0.42 | -0.30 | -0.37 |
| EPS fr Continuing Ops. | -0.26 | -0.42 | -0.30 | -0.37 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.26 | -0.42 | -0.30 | -0.37 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.26 | -0.42 | -0.30 | -0.37 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.26 | -0.42 | -0.30 | -0.37 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with CUR
- Portfolio NameUser Type
- Userdennis diamonds
- UserMy Folly
- ContributorStem Cell Stocks
- UserRAPTOR SPRTD-0902092107
- UserBlogue's Picks
- Userbrownmark68 Portfolio 1
- UserBENIRANS II
- UserEnergy and Options
Latest CUR Headlines from TheStreet
- 9 Biotech Penny Stocks to Buy 08.31.10 | 10:08 am
- Interstate Hotel, Neuralstem: Midday Volume Plays 12.18.09 | 01:12 pm
- Four Must-See Charts: Stem Cell Stocks 07.02.09 | 03:07 pm
- Stem cell firms jump on Obama policy plans 03.06.09 | 06:03 pm
- Wednesday's Health Winners & Losers 09.19.07 | 04:09 pm
Press Releases for CUR
- DiagnoCure To Host Q2 2012 Conference Call And Webcast - PR Newswire 05.30.12 | 07:05 am
- PCA3 Test Featured At American Urological Association Meeting - PR Newswire 05.25.12 | 07:05 am
- Neuralstem CEO To Present At The World Stem Cells And Regenerative Medicine Congress In London - PR Newswire 05.21.12 | 09:05 am
- DiagnoCure Issues Statement On Acquisition Of Gen-Probe By Hologic - PR Newswire 05.01.12 | 12:05 pm
- Neuralstem ALS Stem Cell Trial Interim Results Reported In The Journal, STEM CELLS - PR Newswire 03.28.12 | 09:03 am
- Fourteenth Patient Dosed In Neuralstem ALS Stem Cell Trial - PR Newswire 03.07.12 | 09:03 am
- PROGENSA® PCA3 Featured At European Association Of Urology Congress In Paris - PR Newswire 02.29.12 | 04:02 pm
- FDA Approves Gen-Probe's PROGENSA® PCA3 Assay, First Urine-Based Molecular Test To Help Determine Need For Repeat Prostate Biopsies - PR Newswire 02.15.12 | 07:02 am
- Neuralstem Announces Closing Of $5.2-Million Registered Direct Offering - PR Newswire 02.14.12 | 11:02 am
- Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2012 - PR Newswire 02.08.12 | 09:02 am
Partner Headlines for CUR
- End-of-Day Market Summary for November 23, 2011 - Benzinga 11.23.11 | 04:11 pm
- Neuralstem Loses $0.08/Share in Q2 - Seeking Alpha 08.11.11 | 09:08 am
- Zacks' Voice of the People highlights opportunities with Citigroup, Neuralstem, Primerica, PDL Biopharma - Press Releases - Zacks 04.28.10 | 09:04 am
- Data Mining - With Your OWN Spreadsheets - Voice of the People - Zacks 04.27.10 | 06:04 pm
